FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease

​Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s disease.

The post FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.